Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

MLA

Richardson, Paul G., et al. “Ibrutinib Alone or with Dexamethasone for Relapsed or Relapsed and Refractory Multiple Myeloma: Phase 2 Trial Results.” British Journal of Haematology, vol. 180, no. 6, Mar. 2018, pp. 821–30. EBSCOhost, https://doi.org/10.1111/bjh.15058.

APA

Richardson, P. G., Bensinger, W. I., Huff, C. A., Costello, C. L., Lendvai, N., Berdeja, J. G., Anderson, L. D., Jr, Siegel, D. S., Lebovic, D., Jagannath, S., Laubach, J. P., Stockerl-Goldstein, K. E., Kwei, L., Clow, F., Elias, L., Salman, Z., Graef, T., Bilotti, E., & Vij, R. (2018). Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 180(6), 821–830. https://doi.org/10.1111/bjh.15058

Chicago

Richardson, Paul G, William I Bensinger, Carol Ann Huff, Caitlin L Costello, Nikoletta Lendvai, Jesus G Berdeja, Larry D Anderson Jr, et al. 2018. “Ibrutinib Alone or with Dexamethasone for Relapsed or Relapsed and Refractory Multiple Myeloma: Phase 2 Trial Results.” British Journal of Haematology 180 (6): 821–30. doi:10.1111/bjh.15058.